Evidence map›Paper›PMID 40707743›Full record

ArticleNPJ digital medicine2025

Equity-enhanced glaucoma progression prediction from OCT with knowledge distillation.

Sulaiman O Afolabi, Leila Gheisi, Jing Shan, Lucy Q Shen, Mengyu Wang, Min Shi

Abstract read
In one paragraph

Article in NPJ digital medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sulaiman O AfolabiMedical AI Lab, School of Computing and Informatics, University of Louisiana at Lafayette, Lafayette, LA, USA.
Leila GheisiMedical AI Lab, School of Computing and Informatics, University of Louisiana at Lafayette, Lafayette, LA, USA.
Jing ShanDepartment of Ophthalmology, University of California San Francisco, San Francisco, CA, USA.
Lucy Q ShenMassachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.
Mengyu WangHarvard Ophthalmology AI Lab, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.
Min ShiMedical AI Lab, School of Computing and Informatics, University of Louisiana at Lafayette, Lafayette, LA, USA. min.shi@louisiana.edu.

Funding

VISION RESEARCHP30EY003790 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Patricia Ann D'Amore · 1985 to 2026
$25.5M
Developing Population-Generalizable Deep Learning Models for Automated Glaucoma ScreeningR01EY036222 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Mengyu Wang · 2024 to 2026
$2.0M
Personalizing Circumpapillary Retinal Nerve Fiber Layer Thickness Norms for GlaucomaR21EY035298 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI WANG, MENGYU · 2023 to 2023
$557k
Louisiana Board of Regents LEQSF(2025-28)-RD-A-19NEI NIH HHS P30 EY003790NEI NIH HHS R01 EY036222NEI NIH HHS R21 EY035298NIH HHS R01 EY036222
6 · The paper itself

Abstract

Glaucoma is a progressive disease that can lead to permanent vision loss, making progression prediction vital for guiding effective treatment. Deep learning aids progression prediction but may yield unequal outcomes across demographic groups. We proposed a model called FairDist, which utilized baseline optical coherence tomography scans to predict glaucoma progression. An equity-aware EfficientNet was trained for glaucoma detection, which was then adapted for progression prediction with knowledge distillation. Model accuracy was measured by the AUC, Sensitivity, Specificity, and equity was assessed using equity-scaled AUC, which adjusts AUC by accounting for subgroup disparities. The mean deviation, fast progression, and total deviation pointwise progression were explored in this work. For both progression types, FairDist achieved the highest AUC and equity-scaled AUC for gender and racial groups, compared to methods with and without unfairness mitigation strategies. FairDist can be generalized to other disease progression prediction tasks to potentially achieve improved performance and fairness.

Identifiers

PMID40707743
PMCPMC12289865

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.